Total Payments
$18,698
2024 Payments
$12,649
Companies
19
Transactions
140
Medicare Patients
3,585
Medicare Billing
$2.3M
Payment Breakdown by Category
Consulting$9,330 (49.9%)
Food & Beverage$6,736 (36.0%)
Other$1,390 (7.4%)
Travel$1,242 (6.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,330 | 6 | 49.9% |
| Food and Beverage | $6,736 | 125 | 36.0% |
| Honoraria | $1,390 | 1 | 7.4% |
| Travel and Lodging | $1,242 | 8 | 6.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $4,396 | 15 | $0 (2024) |
| Ocular Therapeutix, Inc. | $3,177 | 3 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $2,971 | 6 | $0 (2024) |
| Alimera Sciences, Inc. | $1,757 | 10 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $1,718 | 14 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $1,349 | 29 | $0 (2024) |
| Alcon Vision LLC | $602.28 | 5 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $527.12 | 15 | $0 (2024) |
| Astellas Pharma US Inc | $464.42 | 9 | $0 (2024) |
| Genentech USA, Inc. | $416.66 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,649 | 73 | Regeneron Pharmaceuticals, Inc. ($4,012) |
| 2023 | $2,246 | 39 | Regeneron Healthcare Solutions, Inc. ($696.90) |
| 2022 | $887.34 | 10 | Genentech, Inc. ($192.81) |
| 2021 | $2,799 | 17 | Bausch & Lomb, a division of Bausch Health US, LLC ($1,718) |
| 2019 | $116.62 | 1 | Genentech USA, Inc. ($116.62) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $32.92 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/18/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Ophthalmology | ||||||
| 12/14/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug), VISUDYNE | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Ophthalmology | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $38.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $127.31 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/04/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/11/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $115.61 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $8.55 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: Ophthalmology | ||||||
| 10/31/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.53 | General |
| Category: Ophthalmology | ||||||
| 10/29/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: EYE CARE | ||||||
| 10/23/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/21/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,480.00 | General |
| 10/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $31.61 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Ophthalmology | ||||||
| 10/17/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $9.38 | General |
| Category: Ophthalmology | ||||||
| 10/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: Ophthalmology | ||||||
| 10/10/2024 | Ocular Therapeutix, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,480.00 | General |
| 08/30/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/23/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $17.05 | General |
| 08/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $34.78 | General |
| Category: Ophthalmology | ||||||
| 08/14/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/14/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.56 | General |
| Category: EYE CARE | ||||||
| 07/30/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,423 | 9,541 | $7.9M | $2.0M |
| 2022 | 10 | 786 | 1,164 | $883,416 | $285,060 |
| 2021 | 11 | 292 | 338 | $99,827 | $20,704 |
| 2020 | 4 | 84 | 88 | $14,286 | $3,443 |
Total Patients
3,585
Total Services
11,131
Medicare Billing
$2.3M
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 260 | 1,620 | $4.4M | $1.1M | 25.5% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 55 | 900 | $756,000 | $195,859 | 25.9% |
| J3590 | Unclassified biologics | Office | 2023 | 40 | 73 | $450,281 | $116,637 | 25.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 393 | 999 | $468,864 | $97,433 | 20.8% |
| J3490 | Unclassified drugs | Office | 2023 | 29 | 52 | $385,719 | $97,332 | 25.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 34 | 386 | $289,075 | $68,022 | 23.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 14 | 2,340 | $259,921 | $66,360 | 25.5% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 488 | 727 | $287,892 | $65,628 | 22.8% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 18 | 435 | $196,185 | $52,357 | 26.7% |
| 92134 | Imaging of retina | Office | 2023 | 703 | 1,552 | $197,104 | $46,026 | 23.4% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 14 | 14 | $50,690 | $12,597 | 24.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 99 | 99 | $46,431 | $9,872 | 21.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $41,159 | $8,954 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 49 | $19,600 | $4,788 | 24.4% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 32 | 33 | $13,002 | $3,199 | 24.6% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 15 | 15 | $11,280 | $2,723 | 24.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 21 | 31 | $10,920 | $2,264 | 20.7% |
| 92250 | Photography of the retina | Office | 2023 | 61 | 67 | $7,772 | $1,805 | 23.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 14 | 14 | $3,920 | $971.53 | 24.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 56 | $700.00 | $46.16 | 6.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 94 | 310 | $624,984 | $219,594 | 35.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 134 | 170 | $90,356 | $17,008 | 18.8% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 133 | 141 | $39,644 | $13,820 | 34.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 11 | 63 | $40,950 | $12,763 | 31.2% |
| 92134 | Imaging of retina | Office | 2022 | 227 | 275 | $38,473 | $8,562 | 22.3% |
About Dr. Effie Rahman, MD
Dr. Effie Rahman, MD is a Retina Specialist healthcare provider based in Bellaire, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2016. The National Provider Identifier (NPI) number assigned to this provider is 1154777969.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Effie Rahman, MD has received a total of $18,698 in payments from pharmaceutical and medical device companies, with $12,649 received in 2024. These payments were reported across 140 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($9,330).
As a Medicare-enrolled provider, Rahman has provided services to 3,585 Medicare beneficiaries, totaling 11,131 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Bellaire, TX
- Active Since 05/11/2016
- Last Updated 03/10/2022
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1154777969
Products in Payments
- EYLEA HD (Biological) $4,700
- EYP-1901 (Drug) $1,949
- STELLARIS (Device) $1,718
- ILUVIEN (Drug) $1,589
- YUTIQ (Drug) $1,174
- EYLEA (Biological) $1,044
- Constellation (Device) $467.12
- Syfovre (Drug) $436.42
- Vabysmo (Drug) $318.12
- XIPERE (Drug) $230.77
- DEXTENZA (Drug) $216.60
- Izervay (Drug) $203.94
- BYOOVIZ (Biological) $195.98
- Lucentis (Biological) $116.62
- SUSVIMO (Drug) $101.28
- VABYSMO (Drug) $91.53
- ACTHAR (Biological) $71.63
- OZURDEX (Drug) $46.11
- Cimerli (Biological) $17.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Retina Specialist Doctors in Bellaire
Charles Wykoff, Md, Phd, MD, PHD
Retina Specialist — Payments: $1.7M
Retina Specialist $1.7M
Dr. Emmanuel Chang, Md/Phd, MD/PHD
Retina Specialist — Payments: $288,954
Retina Specialist $288,954
Dr. Hasenin Al-Khersan, Md, MD
Retina Specialist — Payments: $29,443
Retina Specialist $29,443
Dr. Patrick Staropoli, Md, MD
Retina Specialist — Payments: $14,253
Retina Specialist $14,253